Gene expression
Do miRNAs plus cytokines flag deadly COVID-19?
Open access · cc by · source: Europe PMC
In 166 hospitalized COVID-19 patients, combining 171 microRNAomes with 25 cytokines discriminated severe disease better than either alone; CCL20, IL6, IL10, and miR-451a were key fatality correlates.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
The gain came from the combination, which is a stronger claim than a single panel performing well.
Combining data types improves classification over either alone. Integrated miRNA plus cytokine/chemokine profiling classified severe cases more accurately than either input, with severity-specific links separating patients whose cytokine levels were otherwise similar.
Evidence for the claim as stated.
Study at a glance
- Design
- Cohort — Two-centre UK COVID-19 cohort integrating circulating microRNAomes with 25 cytokines/chemokines, including leftover hospital blood
- N
- N=166 · 166 patients (Cohort 1 n=58 with 171 microRNAomes; Cohort 2 n=108); 337 samples from 4 hospitals
- Population
- Hospitalized COVID-19 patients in two UK centres (including leftover-blood sampling)
- Outcome
- Discrimination of severe vs milder COVID-19 and correlates of fatal disease (CC + miRNA signature)
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Do miRNAs plus cytokines flag deadly COVID-19?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
171 microRNAomes from 58 Cohort-1 patients.
we determined 171 microRNAomes from 58 hospitalized COVID-19 patients (Cohort 1) and levels of 25 cytokines and chemokines (CC) in the same samples.
337 samples from 166 patients at 4 hospitals.
including whole miRNAome and multiplex CC analysis of 337 samples from 166 patients from 4 hospitals and two different geographical locations in the UK.
Key findings
miRNA+CC classified severe cases more accurately than miRNA or CC alone. Severity-specific miRNA–CC links (e.g., IL6, CCL20) separated patients with similar cytokine levels. An 8 CC / 3 miRNA fatal-disease signature included CCL20, IL6, IL10, and miR-451a. Leftover hospital blood was feasible.
Methodology
Profiled 171 microRNAomes and 25 cytokines/chemokines in 58 Cohort-1 patients, then tested leftover-blood CC/miRNA profiling in 108 Cohort-2 patients from another centre (337 samples, 4 UK hospitals).
Limitations
Associations in hospitalized UK patients do not prove these miRNAs cause death or that the signature should triage care without prospective validation.
Related papers in this topic
Same topic cluster — not a recommendation engine.